索拉非尼的无定形固体分散体用于开发改良型口服生物利用度高的速释片剂，PK研究通过美迪西进行

An amorphous solid dispersion (ASD) of Sorafenib (SOR) was used to develop an immediate release tablet with improved oral bioavailability. The SOR ASD tablets exhibited approximately 50% higher relative bioavailability in dogs than the marketed SOR tablet product, Nexavar®. The pharmacokinetic (PK) study of SOR ASD tablets and Nexavar® tablets was performed by Medicilon.

Reference

Sichen Song, et al. Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion. Int J Pharm. 2021 Dec 15;610:121216. doi: 10.1016/j.ijpharm.2021.121216.